Patent Law Changes Could Help or Hurt Drugmakers

By Conlan, Michael F. | Drug Topics, March 2, 1995 | Go to article overview
Save to active project

Patent Law Changes Could Help or Hurt Drugmakers

Conlan, Michael F., Drug Topics

Changes wrought by an international trade deal could extend the patent lives of more than 100 drugs, bringing millions of dollars of extra profits to brand-name firms and putting off the introduction of cost-cutting generic competition. Some generic companies, already heavily invested in getting a chemical copy to market, may wind up paying royalties to innovator firms.

U.S. law on patent terms was changed from 17 years from date of issuance to 20 years from date of filing, under the Uruguay Round Agreements Act (URAA) amendments to the General Agreement on Tariffs & Trade. Congress approved the wide-ranging world economic pact late last year. The purpose was to bring U.S. laws more in line with those of its trading partners. Under a transitional provision, patents unexpired as of June 8, 1995, could get the 20-year protection if that term is longer than 17 years from the date it was originally granted.

Stephen A. Schondelmeyer, head of the Prime Institute at the University of Minnesota College of Pharmacy, estimates that as many as 120 brand-name drugs may have their patent lives extended by anywhere from "three or four months to three or four years." Already, Merck & Co. has claimed that its lipid-lowering Mevacor (Iovastatin) will get an additional 18 months under URAA, prolonging its exclusive run into 2001. It also believes its antibiotic Noroxin (norfloxacin) is eligible for a 23-month add-on, good until February 2000, and Pepcid (famotidine) would get a two-month extension in 2000.

"Longer patent lives increase the expected profitability from research and development expenditures, with a consequent increase in the rate of technical advance," states a white paper prepared by the Progress & Freedom Foundation. The foundation, a think tank with close ties to House Speaker Newt Gingrich, has said it is designing a plan to restructure the Food & Drug Administration. "For the patient, longer patent protection should increase the availability of new products. The down side is that prices for these products will be higher for a longer period of time."

Schondelmeyer is doing a study on what the URAA delays in the introduction of generics could cost consumers. The National Association of Pharmaceutical Manufacturers (NAPM) and the National Pharmaceutical Alliance (NPA), which represent independent generic manufacturers and suppliers, respectively, are sponsoring the study.

One area of particular concern to the brand and generic industries is the effect of URAA on patent term extensions that can be granted to compensate for delays in the FDA approval process.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Cite this article

Cited article

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

Patent Law Changes Could Help or Hurt Drugmakers


Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?